Results 111 to 120 of about 276,897 (341)

Association of Melanoma-Associated Antigen-A and Program-death ligand 1 Expression and Clinical Outcomes in Urothelial Carcinoma [PDF]

, 2019
Background: The melanoma-associated antigen-A (MAGE-A) and program-death ligand 1 (PD-L1) are present in urothelial carcinoma (UC). We aim to assess survival outcomes in patients with MAGE-A and PD-L1 expression.Methods: Analysis of MAGE-A and PD-L1 ...
Faiena, Izak
core  

Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer. [PDF]

, 2017
Cancer-Testis antigens (CTA) are immunogenic molecules with normal tissue expression restricted to testes but with aberrant expression in up to 30% of non-small cell lung cancers (NSCLCs). Regulation of CTA expression is mediated in part through promoter
Barnett, Stephen A, Boutros, Paul C, Chüeh, Anderly C, Jayachandran, Aparna, John, Thomas, Liew, Mun-Sem, Mariadason, John M, Russell, Prudence A, Starmans, Maud HW, Walkiewicz, Marzena, Wright, Gavin   +10 more
core   +2 more sources

A Single‐Metal‐Doped Nanoplatform for Ferroptosis‐Driven cGAS‐STING Pathway Activation in Hepatocellular Carcinoma Immunotherapy

Advanced Functional Materials, EarlyView.
The cGAS‐STING pathway boosts HCC antitumor immunity but lacks specific activation. Nanoplatform ZMRPF induces HCC ferroptosis via lipid ROS, releasing mtDNA. It synergizes with ZMRPF‐released Mn2⁺ to activate cGAS‐STING, amplifies antigen‐presenting cell activity, reverses HCC immunosuppression, and enables robust systemic antitumor immunity ...
Yuchen Zhang, Shuang Feng, Jie Luo, Kaige Xu, Junfeng Guo, Xingyue Zhang, Mengxue Yuan, Qiang Luo, Yu Huang, Chaoqiang Fan, Kibret Mequanint, Donghui Zhu, Malcolm Xing, Shiming Yang   +13 more
wiley   +1 more source

IFNγ-induced PD-L1 expression is JAK2 but not JAK1 dependent and its inhibition enhances NK-cetuximab mediated ADCC of HNSCC cells [PDF]

, 2014
Programmed death ligand 1 (PD-L1) is an immunosuppressive molecule expressed by many cancer types, including a large proportion of head and neck cancers (HNC), and ligation of its receptor, programmed death 1 (PD-1), induces exhaustion of effector T ...
Concha-Benavente, Fernando, Ferris, Robert L   +1 more
core   +2 more sources

272 PD-L1 CAR engineered K-NK cells to target PD-L1⁺ or PD-L1^- tumors

Regular and Young Investigator Award Abstracts, 2023
Pedro Romero, Andre Kunert, Hardikkumar Jetani, Katarzyna Franciszkiewicz, David Vlerick, Aleksandra Nowicka, Robert Y Igarashi   +6 more
openaire   +2 more sources

Delta-tocotrienol disrupts PD-L1 glycosylation and reverses PD-L1-mediated immune suppression

Biomedicine & Pharmacotherapy
PD-L1-mediated immune escape plays an important role in cancer development and progression. Targeting PD-L1 is consider to be an attractive approach for cancer treatment. PD-L1 is a heavily N-linked glycosylated protein, and the glycosylation of PD-L1 is essential for its ability to interact with its receptor PD-1 to mediate immune suppression.
Zhenou, Sun, Xuan, Ma, Chong, Zhao, Lihong, Fan, Shutao, Yin, Hongbo, Hu   +5 more
openaire   +2 more sources

Membrane Fusion‐Inspired Nanomaterials: Emerging Strategies for Infectious Disease and Cancer Diagnostics

Advanced Healthcare Materials, EarlyView.
Membrane fusion‐inspired nanomaterials offer transformative potential in diagnostics by mimicking natural fusion processes to achieve highly sensitive and specific detection of disease biomarkers. This review highlights recent advancements in nanomaterial functionalization strategies, signal amplification systems, and stimuli‐responsive fusion designs,
Sojeong Lee, Khulan Nyamzaya, Jueun Han, Yejin Song, Jihee Lee, Jung Hyun Jo, Seungmin Bang, Eun‐Kyung Lim, Seungjoo Haam, Eunjung Kim   +9 more
wiley   +1 more source

Rigid, bivalent CTLA-4 binding to CD80 is required to disrupt the cis CD80/PD-L1 interaction

Cell Reports
Summary: The CTLA-4 and PD-1 checkpoints control immune responses and are key targets in immunotherapy. Both pathways are connected via a cis interaction between CD80 and PD-L1, the ligands for CTLA-4 and PD-1, respectively. This cis interaction prevents
Maximillian A. Robinson, Alan Kennedy, Carolina T. Orozco, Hung-Chang Chen, Erin Waters, Dalisay Giovacchini, Kay Yeung, Lily Filer, Claudia Hinze, Christopher Lloyd, Simon J. Dovedi, David M. Sansom   +11 more
doaj   +1 more source

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Cell & Bioscience, 2018
Antibody blockade of the PD-1/PD-L1 pathway has elicited durable antitumor responses in the therapy of a broad spectrum of cancers. PD-L1 is constitutively expressed in certain tumors and host immune cells, and its expression can be induced or maintained
Fei Tang, Pan Zheng
doaj   +1 more source

Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis [PDF]

, 2020
Qiang Zeng, Zhigang Liu, Ting Liu
openalex   +1 more source